Home > Divisions / Units / Centres > Gastroenterology & Hepatology > Publication

Gastroenterology & Hepatology

Staff List | Research | Publication | Educational / Clinical Meeting | Clinical Service

Publication

1. Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009; 9:256-64.
2. Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma J, Zou B, Gu Q, Wang J, Pang R, Lan HY, Wong BC. Peroxisome proliferator-activated receptor-{gamma} contributes to the inhibitory effects of embelin on colon carcinogenesis. Cancer Research 2009; 69(11): 4776-83.
3. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135:1192-9.
4. Lai CL, Yuen MF. Chronic hepatitis B - new goals, new treatment. N Engl J Med. 2008; 359:2488-91.
5. Lai CL, Yuen MF. The natural history and treatment of CHB: Critical evaluation of treatment criteria and endpoints. Ann Intern Med 2007; 147:58-61.
6. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology Guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102(8): 1808-25.
7. Lai CL, Gane E, Liaw YF, Hsu CW, Thongawat S, Wang YM, Chen YG, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, DiBisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, for the GLOBE Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-88.
8. Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y, Zhuang Z, Zhang Z, Kung HF, Wong BCY. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007; 132(3): 1066-76.
9. Yuen MF, Fong DYT, Wong DKH, Yuen JCH, Fung J, Lai CL. HBV DNA levels at week 4 of lamivudine treatment predict 5-year "ideal response" Hepatology 2007;46(6):1695-1703.
10. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-20.

Exceptional Publications

1. Wong BCY, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WHC, Yuen ST, Leung SY, Fong DYT, Ho J, Ching CK, Chen JS and the China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region in China: A randomized controlled trial JAMA 2004; 291(2): 187-194.
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. The Lancet 2003; 362(9401):2089-2094.
3. Lai CL, Chien RN, Leung NWY, Chang TT, Kwan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF, Asian Hepatitis Lamivudine Study Groups. A one year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 1998; 339(2):61-68.